A peer-reviewed clinical case series or surveillance report documenting cefiderocol-resistant carbapenem-resistant Acinetobacter baumannii (CRAB) or carbapenem-resistant Pseudomonas aeruginosa with ≥10 isolates from a single US or European hospital network will be published by 2027-04-20, marking the first major US/EU cefiderocol resistance cluster following Shionogi's BARDA contract for cefiderocol (CIDRAP 2026-04-09) and the expert statement on cefiderocol's role in CR-NF-GNB infections (PMC12924807).

System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.

Moderate confidence

Confidence in this assessment

50%

The evidence is meaningful, but there is still material uncertainty. Based on 0 linked evidence items and assessed against 365D.

Assessed through 365D0 linked evidence itemsTracking since Apr 20, 2026

How this assessment will be evaluated

The criteria the system uses to determine whether this assessment is borne out by the stated horizon.

Automated

Method

Evidence Match

The condition the system checks for when evaluating this assessment.

Minimum source quality

T1Primary Institutional

Evidence must meet or exceed this credibility tier to count toward evaluation.

Required terms

cefiderocol-resistantcarbapenem-resistantpeer-reviewedacinetobacter

Evidence quality mix

Tracking since Apr 20, 2026.

Integrity referencesCryptographic hashes for verification

Registration

Integrity anchor

Brier 0.202

19 resolved novel pathogen detection predictions.

Scope synthesis

The current analyst narrative for this scope.

Open synthesis →

AMR evidence coverage critically degraded this cycle; two hypotheses resolve in 5 days without supporting data; PubMed failure is the primary bottleneck.

Evidence linked to this assessment

0 linked items.

No linked evidence is available for this assessment yet.